Novavax, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparative period is Q1 2023. Novavax is a biotechnology company whose commercial program is currently focused on COVID-19 vaccines, with additional vaccine candidates and Matrix-M adjuvant partnerships.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Total revenue | $93.9 million | $81.0 million |
| Product sales | $82.3 million | $(7.5) million |
| Grants | None | $87.4 million |
| Royalties and other | $11.5 million | $1.0 million |
| Cost of sales | $59.2 million | $34.1 million |
| Research and development | $92.7 million | $247.1 million |
| Selling, general and administrative | $86.8 million | $112.5 million |
| Operating loss | $(144.8) million | $(312.8) million |
| Net loss / diluted loss per share | $(147.6) million / $(1.05) | $(293.9) million / $(3.41) |
| Operating cash flow | $(83.6) million | $(325.6) million |
| Cash, cash equivalents and restricted cash | $495.9 million | $583.8 million at Dec. 31, 2023 |
At March 31, 2024, cash and cash equivalents were $480.6 million. Current assets were $727.1 million versus current liabilities of $804.4 million, indicating a working capital deficiency. Total liabilities were $2.22 billion and stockholders’ deficit was $867.1 million. Convertible notes had $175.3 million principal outstanding and a $168.4 million carrying value; the notes bear 5.00% interest and mature in 2027. The filing does not provide a single headline gross-margin figure.
Changes versus Q1 2023
- Revenue rose $12.9 million, as higher COVID-19 vaccine sales and Matrix-M adjuvant and license revenue more than offset the absence of $87.4 million of grant revenue. Q1 2023 product sales were negative because of a $64.7 million credit for Australian doses removed from the market after a lot failed stability specifications.
- Net loss narrowed by $146.4 million, primarily reflecting lower R&D spending. R&D and SG&A together fell approximately 50% year over year; the filing attributes much of the R&D decline to reduced COVID-19 manufacturing and support spending and a $26.6 million benefit from settling a Fujifilm dispute.
- Operating cash use improved by $242.0 million. Cash and restricted cash nevertheless declined $87.9 million during the quarter.
- Cost of sales increased to $59.2 million and included $8.8 million of inventory write-downs and $6.0 million of unutilized manufacturing capacity costs.
Outlook, risks and unusual items
- Sanofi agreement, subsequent event: Effective May 10, 2024, Novavax entered into a collaboration and license agreement and a share subscription agreement expected to provide $568.8 million in Q2 2024: a $500 million nonrefundable upfront payment and $68.8 million for 6,880,481 shares at $10 per share. The agreements also provide for potential milestones and royalties; these are contingent, not assured. Sanofi receives rights covering Novavax’s COVID-19 products, combination vaccines and certain Matrix-M adjuvant products. The parties plan to commercialize COVID-19 vaccines together beginning in 2025.
- Management said the Sanofi proceeds, together with cost-reduction and commercial plans, alleviated the substantial doubt about the company’s ability to continue as a going concern for one year after issuance of the financial statements. The forecast remains sensitive to vaccine revenue, execution of cost measures, authorizations, demand, delivery and customer adoption.
- Novavax expects its updated COVID-19 vaccine to be available at U.S. pharmacy retailers in September 2024. It completed submission of a BLA for its prototype vaccine and aligned with FDA on an EUA pathway for the updated 2024–2025 vaccine. EUA rather than BLA status could affect commercialization. Updated product authorization, supply readiness and market acceptance remain uncertain.
- The company plans to initiate Phase 3 trials for its COVID-influenza combination and standalone influenza candidates in the second half of 2024; a potential combination-vaccine launch is described for fall 2026. These are forward-looking expectations, not guaranteed outcomes.
- Restructuring continues. Novavax expects the full annual impact of the 2023 plan in 2024 and of the 2024 cost-reduction plan in 2025; approximately 85% of the latter plan’s annual impact, excluding one-time charges, is expected in 2024. Q1 restructuring charges were $6.1 million.
- Gavi settlement: Novavax paid $75 million in February 2024 and owes up to $400 million in deferred payments through 2028, potentially reduced by qualifying vaccine credits; it also granted up to $225 million in additional credits. The settlement resolved the arbitration, but future cash burden depends partly on qualifying sales and credits.
- Advance purchase agreement exposure: Australia canceled scheduled doses, reducing contract value by $54 million; authorization and an amendment remain uncertain. Novavax does not expect approval using Canadian BMC-produced antigen by the December 31, 2024 deadline. If Canada terminates its agreement, $28 million of deferred revenue would become refundable and approximately $224 million of future contract value would be lost. The UK is discussing treatment of a remaining $112.5 million upfront amount.
- A $47 million securities-class-action settlement was recorded with an expected insurance recovery; final court approval was pending as of the filing. Derivative litigation remains pending, and its financial impact is not estimable.
- Novavax relies substantially on external manufacturing and finishing partners. Delays, regulatory setbacks, supply constraints, inadequate demand, or failure to meet APA obligations could lead to refunds or reduced payments. The company also reports foreign-exchange exposure and has not entered into currency hedges.
Investor verification points
- Confirm receipt and accounting treatment of Sanofi’s $568.8 million Q2 proceeds, and track the conditions and timing attached to potential milestones and royalties.
- Verify FDA decisions and readiness for the 2024–2025 vaccine season, including the targeted September availability, product presentation and distribution arrangements.
- Monitor cash use, working capital, restructuring savings and the timing and amount of Gavi payments or credits.
- Track Australia and Canada APA amendments, related authorization milestones, and the UK’s treatment of the remaining upfront payment.
- Review subsequent developments in the securities settlement and derivative litigation, as well as manufacturing-partner concentration and inventory write-downs.